Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 25.01.2022 at 9:00 AM CET
Settings

Settings

Goto Application

1. NZ275749 - Suspension of loteprednol etabonate

Office
New Zealand
Application Number 275749
Application Date 26.04.1996
Publication Number 275749
Publication Date 24.02.1998
Grant Number 275749
Grant Date 02.06.1998
Publication Kind B
IPC
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61K 47/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 9/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
A61K 47/30
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
CPC
A61K 9/0043
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0043Nose
A61K 9/0048
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
0012Galenical forms characterised by the site of application
0048Eye, e.g. artificial tears
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61K 31/715
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
A61K 31/74
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
74Synthetic polymeric materials
A61K 31/79
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
74Synthetic polymeric materials
785Polymers containing nitrogen
787containing heterocyclic rings having nitrogen as a ring hetero atom
79Polymers of vinyl pyrrolidone
Applicants PHARMOS CORP
Inventors Guy, Yaacov, J
Friedman, Doron
Agents PIPERS
Priority Data 08142743 25.10.1993 US
Title
(EN) Suspension of loteprednol etabonate
Abstract
(EN) The specification provides compositions for ophthalmic or otolaryngological anti-inflammatory use comprising: (A) a corticosteroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight; (B) a nonionic polymer in an aqueous medium; and (C) a nonionic surface active agent in an amount sufficient to retain the corticosteroid and nonionic polymer in suspension. (D) a nonionic tonicity agent in an amount sufficient to achieve isotonicity, wherein the molar ratio of (A) : (B) : (C) is about 1:0.1:0.05 to 1:20:1. The corticosteroid is selected from the group consisting of soft steroids having anti-inflammatory activity. The corticosteroid is preferably loteprednol etabonate present in an amount of about 0.5 and 1% by weight. The nonionic polymer is a water soluble polymer selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, dextrin and cyclodextrin and is present in an amount of about 0.2 to 2% by weight. The preferred nonionic polymer is polyvinylpyrrolidone present in an amount of about 0.4 to 1% by weight. The nonionic surface active agent is preferably tyloxapol and is present in an amount of about 0.1 to 0.6% by weight. The nonionic tonicity agent is a nonionic diol, preferably glycerol or mannitol, present in an amount of about 1.5 to 4% by weight.